Shanghai Yizhong Pharmaceutical Co Ltd (688091) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Shanghai Yizhong Pharmaceutical Co Ltd stock ¥7.02, price ¥33.40, that is 79.0% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Shanghai Yizhong Pharmaceutical Co Ltd
688091 · SHGFar too expensive (fair value 79% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range ¥19.57 – ¥96.07 · fair‑value band ¥5.85 – ¥8.53 · the ¥33.40 price screens above the ¥7.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Shanghai Yizhong Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China.
Show moreShow less
It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc.
The company was founded in 2009 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Yizhong Pharmaceutical Co Ltd (688091) currently trades at ¥33.40, while our model-based Fair Value estimate is ¥7.02, 79% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥13.77 per share, and 0 of the 16 models we run sit above the ¥33.40 price.
Bear case: the Asset-Based group reads lowest at ¥2.59, and 16 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥5.85 (bear) to ¥8.53 (bull), the price of ¥33.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shanghai Yizhong Pharmaceutical Co Ltd reported revenue of 317M CNY in FY2025 versus 4.1M CNY in FY2021, a compound +197.0%/yr. Reported net income was 64.1M CNY in FY2025.
Key figures
Market cap 6.9B CNY (≈ $1.0B) Small · P/E ratio 98.2 · P/S ratio 21.5 · EPS (TTM) ¥0.3400 · Net margin 21.4% · Return on equity 4.7% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 20.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (medium confidence).
What moves the price
The share trades about 48% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −79%, 688091 screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
688091 screens overvalued: fair value 79% below the price. Compare with Merck KGaA →
Compare Shanghai Yizhong Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs 688091 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.66 | ¥53.04 | +11% | vs 688091 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,870 | ₹1,983 | +6% | vs 688091 |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs 688091 |
| Merck KGaA MRK | €150.75 | €108.83 | −28% | vs 688091 |
| Galderma Group GALD | CHF 187.15 | CHF 112.46 | −40% | vs 688091 |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs 688091 |
| Sandoz Group SDZ | CHF 83.00 | CHF 40.54 | −51% | vs 688091 |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs 688091 |
| Divi's Laboratories Limited DIVISLAB | ₹11,150 | ₹1,567 | −86% | vs 688091 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Yizhong Pharmaceutical Co Ltd (688091) overvalued or undervalued?
What is the fair value of 688091?
What is the quality score of 688091?
What is the price target for Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the Shanghai Yizhong Pharmaceutical Co Ltd stock forecast for 2026?
What is the revenue of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the intrinsic value of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
Is Shanghai Yizhong Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 688091?
How much is Shanghai Yizhong Pharmaceutical Co Ltd worth?
What do the bullish and bearish scenarios say about 688091?
What is the P/E ratio of 688091?
How solid is the balance sheet of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
How far is 688091 from its 52-week high?
Which stocks are comparable to Shanghai Yizhong Pharmaceutical Co Ltd?
Is Shanghai Yizhong Pharmaceutical Co Ltd stock attractive at the current price?
How is the fair value of 688091 calculated?
Is it still worth investing in stocks now?
What is the share price of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What should I pay attention to with Shanghai Yizhong Pharmaceutical Co Ltd right now?
Key figures of Shanghai Yizhong Pharmaceutical Co Ltd
How large is the market capitalisation of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the P/S ratio of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What are the earnings per share of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the net margin of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the return on equity of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the EBIT return on assets of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
What is the operating margin of Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
How fast is revenue growing at Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
How fast are earnings growing at Shanghai Yizhong Pharmaceutical Co Ltd (688091)?
How much free cash flow does Shanghai Yizhong Pharmaceutical Co Ltd (688091) generate?
How much net cash does Shanghai Yizhong Pharmaceutical Co Ltd (688091) hold?
Watch Shanghai Yizhong Pharmaceutical Co Ltd in the live analysis
One click puts Shanghai Yizhong Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.